Regenerative
Medicines
for Chronic Diseases
Progentos is developing a new approach to treating multiple sclerosis that stimulates the body’s natural repair mechanisms.
The Unmet Need
Multiple sclerosis (MS) is a neurological disease that affects nearly 1 million people in the United States. MS destroys myelin, which insulates and protects axons in the brain. Like electrical wires that have been stripped of their insulation, nerves with damaged myelin cannot send signals through the brain.
Patients with MS experience a variety of symptoms ranging from visual issues, numbness and tingling, to trouble with coordination, cognitive challenges, and fatigue.
Progentos Approach
Regenerating myelin to repair the damage caused by MS
The myelin sheath is generated by specialized cells called oligodendrocytes. Progentos aims to develop novel, first in class small-molecule therapeutics to activate oligodendrocyte progenitor cells to regenerate oligodendrocytes and thus replace myelin lost to MS.
There is a significant unmet need for a remyelinating therapeutic that could support axonal health or potentially even allow patients to recover function lost to MS. Approved immunomodulatory therapies for MS are effective in slowing disease progression by suppressing the immune system and reducing attacks on the central nervous system myelin. However, none of these products repair the damage that patients have already accrued.
Progentos scientists have discovered a novel target and new chemical entities for remyelination in MS
Our scientists have identified and validated a novel target that generates clear and compelling remyelination in pre-clinical studies. Our compounds are designed to activate progenitor cells in the brain to form new oligodendrocytes and remyelinate neurons. Remyelination could prevent further decline or, potentially, even restore function.
We are developing a regenerative medicine for MS that can improve quality of life for patients.
LEADERSHIP
Management Team
Board of Directors
